Biotechnology News and Research

RSS

Study: Staring at deep red light can significantly improve declining eyesight

Staring at a deep red light for three minutes a day can significantly improve declining eyesight, finds a new UCL-led study, the first of its kind in humans.

29 Jun 2020

Noile-Immune Biotech and C4U team up to develop CRISPR/Cas3 technology

Noile-Immune Biotech Inc., ("Noile-Immune") and C4U Corporation, ("C4U") announced that they have entered into an agreement on joint research and commercialization of next-generation allogeneic gene-modified immune cell therapy combining C4U's CRISPR/Cas3 genome editing technology and Noile-Immune's PRIME (Proliferation inducing and migration enhancing) technology designed to improve proliferation and trafficking of immune cells into solid tumors.

27 Jun 2020

Chemically engineered peptides could help fight persistent human health challenges

Chemically engineered peptides, designed and developed by a team of researchers at Rensselaer Polytechnic Institute, could prove valuable in the battle against some of the most persistent human health challenges.

26 Jun 2020

New steroid compounds from deep-water starfish show anticancer activity

Russian scientists from Far Eastern Federal University, G. B. Elyakov Pacific Institute of Bioorganic Chemistry, and A.V. Zhirmunsky National Scientific Center for Marine Biology have discovered four new steroid substances which target cells of human breast cancer, and colorectal carcinoma.

26 Jun 2020

Entos Pharmaceuticals selects two lead DNA vaccine candidates for COVID-19

Entos Pharmaceuticals, a healthcare biotechnology company developing nucleic acid medicines with its Fusogenix drug delivery platform, today announced the selection of two lead candidates for a pan-coronavirus Fusogenix DNA vaccine from its prototyping program launched at the onset of the global COVID-19 pandemic.

25 Jun 2020

A 'quick and easy' COVID-19 test developed for population-scale screening

Global endeavors to fight the Covid-19 pandemic heavily rely on accurate, fast and frequent tests for the coronavirus SARS-CoV-2 - "test, test, test", as the World Health Organization has bluntly put it.

24 Jun 2020

New virtual incubator can catalyze early-stage drug discovery and development

Samsara BioCapital, a leading life sciences investment firm, Evotec SE, a global drug discovery alliance and development partnership company (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809), and KCK Ltd., a family investment fund, today announced the launch of Autobahn Labs, a novel virtual incubator partnering with top academic and research institutions to catalyze early-stage drug discovery and development.

24 Jun 2020

ILC Therapeutics announces research partnership with University of St Andrews to fight against COVID-19

UK-based biotechnology firm ILC Therapeutics has announced a research partnership with the University of St Andrews in a bid to progress a therapeutic drug which can treat COVID-19 towards clinical trials.

23 Jun 2020

Nicoya receives NRC IRAP funding to develop saliva-based diagnostic test for COVID-19

Nicoya, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, will receive advisory services and up to $299,190 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program to develop a portable COVID-19 diagnostic test called Atlas.

From Nicoya Lifesciences 23 Jun 2020

New method for producing tsetse fly attractants using biotechnology

The tsetse fly occurs in large regions of sub-Saharan Africa. The flies feed on human and animal blood, transmitting trypanosoma in the process - small, single-cell organisms that use the flies as intermediate host and cause a dangerous inflammation of the lymph and nervous system in both animals and humans.

22 Jun 2020

Young adults from disadvantaged neighborhoods show differences in the epigenome

The neighborhood a child grows up in may influence their health for years to come in previously invisible ways.

21 Jun 2020

AFFiRiS AG announces results of phase 1 trial with PD01A in Parkinson's

AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying specific active immunotherapies (SAITs), today announced that detailed results of the phase 1 clinical program with its lead candidate PD01 in early Parkinson's disease (PD) patients were published in the peer-reviewed journal The Lancet Neurology.

18 Jun 2020

Scientists develop peptides that restore balance in gut bacteria and reverse atherosclerosis

Now, a team of scientists at Scripps Research has developed new molecules that can restore the balance in gut bacteria in the intestines and as a result, lowers cholesterol levels and reverses the narrowing of the arteries, also known as atherosclerosis.

18 Jun 2020

C-Path's Transplant Therapeutics Consortium receives positive FDA response for its Letter of Intent

Critical Path Institute announced today that its Transplant Therapeutics Consortium has received a positive response to its Letter of Intent from the U.S. Food and Drug Administration detailing the decision to accept the Composite Biomarker Panel (iBox Scoring System) into the Center for Drug Evaluation and Research (CDER) Biomarker Qualification Program.

17 Jun 2020

Nanosponges could attack and neutralize SARS-COV-2 virus

Nanoparticles cloaked in human lung cell membranes and human immune cell membranes can attract and neutralize the SARS-CoV-2 virus in cell culture, causing the virus to lose its ability to hijack host cells and reproduce.

17 Jun 2020

Scientists isolate powerful SARS-CoV-2 -neutralizing antibodies from COVID-19 patients

A new study has shown that potent antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could help protect against COVID-19 infection. Preliminary results in animal studies have so far proven successful. The study titled, "Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model," was published in the latest issue of the journal Science.

17 Jun 2020

Research team generates comprehensive developmental map of human T-cells

Chintan Parekh, MD, of The Saban Research Institute of Children's Hospital Los Angeles, has led a team of investigators that generated a comprehensive roadmap for how T-cells develop in the human thymus.

16 Jun 2020

Antibody cocktail with potential to treat COVID-19 identified

Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19.

16 Jun 2020

UCLA receives nearly $14 million NIH grant to investigate immunotherapy to destroy HIV

UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.

16 Jun 2020

Combination of antibodies and internal radiation can help fight cervical cancer

The sugar coating on cancer cells helps them thrive, and a new study indicates patients with cervical cancer who make antibodies to those sugars appear to do better when they also receive internal radiation therapy.

16 Jun 2020